Hodgkin Disease Clinical Trials

6 recruiting

Hodgkin Disease Trials at a Glance

8 actively recruiting trials for hodgkin disease are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Bethesda, Bologna, and Changsha. Lead sponsors running hodgkin disease studies include National Cancer Institute (NCI), Medical College of Wisconsin, and IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Browse hodgkin disease trials by phase

Treatments under study

About Hodgkin Disease Clinical Trials

Looking for clinical trials for Hodgkin Disease? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hodgkin Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hodgkin Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+1 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting

Tissue Collection for Studies of Lymph Cancer

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more
National Cancer Institute (NCI)1,295 enrolled2 locationsNCT01676805
Recruiting
Phase 1

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

LymphomaLeukemiaHodgkin Disease+4 more
Medical College of Wisconsin42 enrolled1 locationNCT05544968
Recruiting
Phase 2

Amping up With PemJAK

Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+2 more
Seda S. Tolu53 enrolled1 locationNCT07283822
Recruiting
Phase 2

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

Hodgkin LymphomaHodgkin DiseaseAdvanced Hodgkin Lymphoma
National Research Center for Hematology, Russia30 enrolled1 locationNCT07209059
Recruiting
Phase 2

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

AMLHodgkin DiseaseNHL
University of Rochester64 enrolled1 locationNCT03739502
Recruiting

Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines

LymphomaHodgkin DiseaseCardiac Imaging+1 more
IRCCS Azienda Ospedaliero-Universitaria di Bologna160 enrolled1 locationNCT06774326
Recruiting
Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Hodgkin Disease Lymphoma
Akeso60 enrolled6 locationsNCT05244642